Shenzhen Kangtai Biological Products Co., Ltd.

AstraZeneca, a British company, hopes to invest $2.5 billion to establish its sixth global strategic R&D center in Beijing. The investment, which will be completed over the next five years, is part of a strategic partnership between AstraZeneca and the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Management Office, and includes multiple research and manufacturing agreements. AstraZeneca expects its headcount in Beijing to increase to 1,700.   AstraZeneca CEO Pascal Soriot said: "This $2.5 billion investment reflects our confidence in Beijing's world-class life science ecosystem, our confidence in the broad opportunities for collaboration and talent acquisition, and our continued commitment to China. Our sixth strategic R&D center will work with Beijing's cutting-edge biology and artificial intelligence science to bring innovative medicines to patients around the world."   Beijing is AstraZeneca's second global strategic R&D center in China after Shanghai, which will be supported by new artificial intelligence and data science laboratories and focus on early research and clinical development.   AstraZeneca said it is also establishing new R&D partnerships in Beijing. This includes a strategic partnership with Beijing Cancer Hospital in translational research, data science and clinical development. The company also signed two collaboration and licensing agreements: one with Harbour BioMed for the discovery of multispecific antibodies and the other with Syneron Bio for the development of macrocyclic peptides.   In addition, AstraZeneca will establish a new joint venture with BioKangtai to develop, produce and commercialize innovative vaccines for respiratory and other infectious diseases. According to AstraZeneca, this will be the company's first and only vaccine production site in China, located in the Beijing Biopark.

AstraZeneca anticipates that the expansion will increase its workforce in the region to 1,700. Credit: Robert Way/Shutterstock. AstraZeneca has announced a $2.5bn investment in the company’s sixth worldwide strategic research and development (R&D) centre in Beijing, China. The initiative, which will take place up to 2029, is part of a strategic collaboration with the Beijing municipal government and the Beijing Economic-Technological Development Area Administrative Office. The new R&D centre will focus on early-stage research and clinical development, supported by data science and an AI lab. It will be located in Beijing International Pharmaceutical Innovation Park, close to the National Medical Products Administration and the biotechs and research hospitals. The expansion will increase AstraZeneca’s workforce in the region to 1,700. The company is forging partnerships in the country, including a strategic collaboration with the Beijing Cancer Hospital aimed at data science, translational research and clinical development. It is entering into two partnerships and licencing agreements with Harbour BioMed for multi-specific antibody discovery, and a third with Syneron Bio for macro-cyclic peptides development. AstraZeneca CEO Pascal Soriot stated: “This $2.5bn investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China.” Harbour BioMed’s partnership includes AstraZeneca’s $105m equity investment. Harbour BioMed will receive $175m in upfront and near-term milestone payments, along with up to $4.4bn in further payments. AstraZeneca will acquire 9.15% Harbour BioMed’s newly issued shares. The agreement involves an option to license several programmes leveraging Harbour’s Harbour Mice fully human antibody technology platform covering various therapeutic areas. Syneron Bio’s strategic partnership involves AstraZeneca offering upfront and potential near-term milestone payments of $75m and up to $3.4bn in further payments. AstraZeneca’s equity investment in Syneron Bio will support the expansion of its Beijing R&D centre. Syneron Bio will provide AstraZeneca with access to its Synova platform, a macrocyclic peptide drug research and development platform. AstraZeneca is launching a joint venture with BioKangtai to develop, manufacture and commercialise vaccines for respiratory and infectious conditions. This facility, located in the Beijing BioPark, will be AstraZeneca’s only vaccine manufacturing site in the country.

iStock, Robert Way The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations. AstraZeneca is betting big money on China, unveiling plans to establish a new global strategic center in the country, alongside a pair of high-value deals with Chinese biotechs. With potential milestone payments, the pharma is putting more than $10 billion overall on the line, In a Friday news release, AstraZeneca unveiled a $2.5 billion investment in Beijing, set to be paid out over the next five years, with an eye toward establishing its sixth global strategic R&D center there. The new research facility will focus on early-stage studies and clinical development, and will “partner with the cutting-edge biology and AI science in Beijing,” CEO Pascal Soriot said in the statement. Alongside its $2.5 billion manufacturing pledge, AstraZeneca on Friday also inked a handful of research collaborations. With Harbour BioMed, based in Shanghai, AstraZeneca will discover and develop next-generation multispecific antibodies. For $175 million upfront and the promise of up to $4.4 billion in development and commercial milestones, AstraZeneca will have the option to license two preclinical immunology programs and will be able to nominate additional targets down the line. AstraZeneca on Friday also joined hands with Beijing-based Syneron Bio to advance oral macrocyclic peptides. AstraZeneca made a $75 million upfront payment and pledged up to $3.4 billion in milestones. The partners have yet to reveal priority indications, only announcing that they will target “chronic diseases, including rare, autoimmune, and metabolic disease.” The pharma also announced that it will work with the Beijing Cancer Hospital for translational research, data science and clinical development, and will also launch a joint vaccine venture with BioKangtai. AstraZeneca’s hefty investment comes amid mounting political pressure on the company—both domestically and internationally. In late 2024, news broke that Chinese authorities were looking into AstraZeneca’s former China president Leon Wang for alleged insurance fraud, according to local financial-focused publication Yicai , which also noted that other top pharma officials were under investigation. Wang was detained by Chinese authorities late last year, and as of February AstraZeneca has said it has had no access to him. Then, last month, during the company’s fourth-quarter and full-year business report, AstraZeneca announced that it was facing a fine of up to approximately $4.5 million in China, in connection with missed import taxes . Meanwhile, President Donald Trump has also been pressuring pharma companies to bring their manufacturing operations to the U.S., reportedly threatening them with tariffs if they don’t. Eli Lilly has since announced a $27 billion infusion into its U.S. operations, earmarked for the construction of four new manufacturing plants to be built over the next five years. J&J followed suit, announcing last week that it will pump $55 billion into its U.S. manufacturing and R&D footprint, to be disbursed over the next four years. The money will help the pharma construct three manufacturing plants as well as expand existing sites for its medicines and MedTech units.